10x Genomics CEO sells 5,000 shares under plan
10x Genomics, Inc. Chief Executive Officer Serge Saxonov sold 5,000 shares of Class A Common Stock in an open-market transaction at a weighted average price of $24.5568 per share on April 14, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
10x Genomics, Inc. Chief Executive Officer Serge Saxonov sold 5,000 shares of Class A Common Stock in an open-market transaction at a weighted average price of $24.5568 per share on April 14, 2026. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2025, indicating it was scheduled in advance.
Following the sale, Saxonov directly holds 1,167,273 shares of Class A Common Stock. He also has indirect holdings through trusts where he serves as trustee, including 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 71,644 shares in the Y/S Pot Trust.
Insider Trade Summary 10b5-1
Net Seller: 5,000 shares
Net Sell
4 txns
Insider
Saxonov Serge
Role
Chief Executive Officer
Sold
5,000 shs ($123K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock | 5,000 | $24.5568 | $123K |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Class A Common Stock — 1,167,273 shares (Direct);
Class A Common Stock — 284,921 shares (Indirect, See footnote)
Footnotes (5)
- F1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $24.49 to $24.70, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F3. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
- F4. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
- F5. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
Key Figures
Shares sold: 5,000 shares
Weighted average sale price: $24.5568 per share
Sale price range: $24.49–$24.70 per share
+5 more
8 metrics
Shares sold
5,000 shares
Open-market sale on April 14, 2026
Weighted average sale price
$24.5568 per share
Class A Common Stock sale
Sale price range
$24.49–$24.70 per share
Multiple trades within stated range
Direct holdings after transaction
1,167,273 shares
Class A Common Stock held directly by CEO
Andromeda Trust holdings
27 shares
Indirect holding; CEO serves as trustee
Y/S Descendants' Trust holdings
213,250 shares
Indirect holding; CEO serves as trustee
Y/S Pot Trust holdings
71,644 shares
Indirect holding; CEO serves as trustee
Rule 10b5-1 plan adoption date
November 29, 2025
Governs timing of the 5,000-share sale
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, Class A Common Stock, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported above reflects the weighted average sale price"
Class A Common Stock financial
"security_title: "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
trustee financial
"for which the Reporting Person serves as trustee"
A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did 10x Genomics (TXG) CEO Serge Saxonov report in this Form 4?
Serge Saxonov reported selling 5,000 shares of 10x Genomics Class A Common Stock at a weighted average price of $24.5568 on April 14, 2026. The filing also updates his remaining direct and trust-held share positions after the transaction.
What indirect 10x Genomics (TXG) holdings are disclosed for the CEO?
The filing lists three trust positions: 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 71,644 shares in the Y/S Pot Trust. In each case, Serge Saxonov is identified as trustee, indicating he has authority over these trust-held shares.
How is the sale price range for the 10x Genomics (TXG) CEO’s trade described?
The Form 4 notes the 5,000-share transaction occurred in multiple trades between $24.49 and $24.70 per share. The reported $24.5568 figure is a weighted average, and the CEO undertakes to provide detailed trade breakdowns upon request to regulators, the issuer, or security holders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates